Novartis to acquire SNV4818 from Synnovation
SNV4818 is an oral drug and is presently being assessed in an ongoing Phase I/II trial for breast cancer.
Drug Development
Congruence secures $39.5m to advance small molecule correctors pipeline
R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia
FDA issues CRL to Aldeyra’s reproxalap drug application
FDA accepts Sun Pharma’s Ilumya sBLA for psoriatic arthritis
Sentynl and PRG partner for Progerinin licence
Biophytis and LynxKite expand alliance to boost AI-driven drug discovery
Novartis wins FDA approval for Cosentyx to treat paediatric HS patients
